citiusonc.com (CTOR) - Dodolan perusahaan

Lambang korporat lan logo Citius Oncology Inc. (CTOR)

Citius Oncology, Inc. (CTOR) bases its future revenues on the rollout of the LYMPHIR drug for lymphoma therapy. However, a high burn rate and fierce competition create financial risks, while development is conducted through clinical alliances. GURU.Markets analytics includes this chart, where the company's trading revenue reflects business dynamics, and the 0.01 mark indicates the current sales level.

Dodolan perusahaan Citius Oncology Inc. (CTOR): kanggo periode 14.08.2024 - 16.11.2026

Rincian analitis perusahaan Citius Oncology Inc. (CTOR)

Analisis komprehensif perusahaan:Citius Oncology, Inc.
Produk asil prodhuksi Citius Oncology

Investors are seeking fundamental supports in the financial statements of Citius Oncology, Inc. (CTOR) to assess business resilience. This indicator captures the actual cash inflow from the sale of products and services. When analyzing the current sales dynamics of Citius Oncology, Inc. (CTOR), it should be noted that a smooth trend line may mask the risk of sharp declines. For biopharmaceuticals, this flow depends directly on the effective implementation of sustainable synthesis methods. Optimizing energy costs in laboratories determines the long-term profitability of operating activities.

Perusahaan pesaing

Pendapatan perusahaan ONC|Pendapatan lan volume dodolan HALO|RVMD (Revolution Medicines, Inc.) - Pendapatan dodolan perusahaan|Pendapatan perusahaan Ascentage Pharma Corp AAPG|Total volume dodolan perusahaan CG Oncology, Inc.|URGN - Pendapatan perusahaan|Bicara Therapeutics Inc. (BCAX) - Dodolan perusahaan|Personalis Inc (PSNL) - Pendapatan perusahaan|ERAS - Pendapatan reged perusahaan|DCTH (Delcath Systems Inc) - Pendapatan lan volume dodolan|Pendapatan perusahaan YMAB|Pendapatan lan volume dodolan AURA|Pendapatan perusahaan CADL (Candel)|Accuray, Inc. - Dodolan perusahaan|SELLAS Life Sciences Group Inc. - Pendapatan perusahaan|ACTU: Dodolan perusahaan|HURA: Pendapatan perusahaan|TARA (Protara) - Dodolan perusahaan|Fate Therapeutics, Inc. - Pendapatan dodolan perusahaan|WHWK (aadibio.com) - Pendapatan lan volume dodolan|TCRX: Pendapatan dodolan perusahaan|Pendapatan perusahaan Champions Oncology (CSBR)|XBiotech - Volume dodolan perusahaan|Pendapatan perusahaan CEL-SCI CVM|Pendapatan reged perusahaan OS Therapies (OSTX)|Radiopharm Theranostics Limited - Pendapatan lan volume dodolan|Total pendapatan perusahaan Artiva Biotherapeutics|ANL (adlainortye.com) - Dodolan perusahaan|Dodolan perusahaan Veru Pharma|TPST (Tempest Therapeutics Inc) - Pendapatan lan volume dodolan|Xilio Therapeutics, Inc. (XLO) - Pendapatan reged perusahaan|Pendapatan perusahaan Enochian BioSciences (RENB)|MURA: Pendapatan tahunan perusahaan|Pendapatan lan volume dodolan KAPA (kairospharma.com)|Pendapatan reged perusahaan OnKure (OKUR)|CytoMed Therapeutics Ltd - Pendapatan lan volume dodolan|curis.com (CRIS) - Dodolan perusahaan|Apollomics Corp (APLM) - Pendapatan perusahaan|Tharimmune - Pendapatan dodolan perusahaan|ADVB (Advanced Biomed Corp) - Pendapatan lan volume dodolan|Dodolan perusahaan Genprex, Inc (GNPX)|Pendapatan lan volume dodolan CLDI|SBFM: Pendapatan tahunan perusahaan|Pendapatan lan volume dodolan XBIO (xeneticbio.com)|Pendapatan lan volume dodolan Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Pendapatan lan volume dodolan|Total pendapatan perusahaan American Oncology Network, Inc.|BGNE: Pendapatan lan volume dodolan|Dodolan perusahaan checkpointtx.com|Pendapatan perusahaan Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Pendapatan reged perusahaan|Pendapatan perusahaan Ikena (IKNA)|NTBL - Total pendapatan perusahaan|Pendapatan perusahaan viracta.com VIRX|morphosys.com (MOR) - Total pendapatan perusahaan|NAYA Biosciences Inc - Pendapatan lan volume dodolan|AAPGV: Pendapatan perusahaan